• Data
    • Overview
    • Clinical notes
    • Images
    • Mother-child
    • Oncology
    • Regulatory grade
    • Truveta Language Model
    • Truveta Live Link
    • Truveta Studio
  • Genomics
  • Solutions
    • Medical devices
    • Life science
    • Public health
    • Healthcare
  • Research
  • Resources
  • About
    • Blog
    • Members
    • Leadership
    • Events & webinars
    • News
    • Careers

Get started
Sign in
Close
Unlocking treatment insights through real-world discontinuation data

Unlocking treatment insights through real-world discontinuation data

by Truveta staff | Aug 4, 2025 | Research

Why do patients stop taking a medication? Was it due to side effects, access barriers, or lack of efficacy? These are not just clinical questions; they’re strategic ones. Understanding treatment discontinuation is essential for improving therapy design, informing...
Lyme disease peaks in June, remains high through August

Lyme disease peaks in June, remains high through August

by Truveta Research | Aug 1, 2025 | Research, Research Insights

62.7% of Lyme cases occurred between May and August, underscoring the heightened risk during late spring and summer. June consistently showed the highest activity, accounting for nearly 1 in 5 cases (19.4%) across observed years. Risk of Lyme remains elevated in...
Infection risk and adoption trends in hemodialysis catheters: New real-world evidence

Infection risk and adoption trends in hemodialysis catheters: New real-world evidence

by Truveta staff | Jul 31, 2025 | Research

Can catheter design impact patient safety? That’s the question of a new peer-reviewed study from Medical Components, Inc. (Medcomp), based on a retrospective analysis of 3,546 catheter insertions captured in Truveta Data. Used to deliver life-sustaining dialysis...
GLP-1 RA prescription trends: January 2018 – June 2025

GLP-1 RA prescription trends: January 2018 – June 2025

by Truveta Research | Jul 24, 2025 | Research

Overall GLP-1 prescribing rates (GLP-1 RA prescriptions per total prescriptions) in June 2025 increased slightly relative to March 2025 (+7.7%). Tirzepatide is now the most prescribed anti-diabetic (ADM) and anti-obesity (AOM) medication (sold as Mounjaro and...
Pediatric fluoride prescriptions fall across the US

Pediatric fluoride prescriptions fall across the US

by Truveta Research | Jul 23, 2025 | Research, Research Insights

The rate of pediatric fluoride prescriptions per all prescriptions decreased by 54.3% from the first quarter of 2022 (5.0 per 1,000 prescriptions) to the second quarter of 2025 (2.3 per 1,000 prescriptions). Across the study period, the 10 US states with lowest...
Truveta experts: Real-world trends in Rituxan biosimilar adoption

Truveta experts: Real-world trends in Rituxan biosimilar adoption

by Truveta staff | Jul 21, 2025 | Research

In this Truveta experts spotlight, Jared Kern and Vidya Venkataraman, PhD explored trends in the use of Rituxan biosimilars between 2018 and 2024. Their analysis of Truveta Data reveals how patient access and switching behavior has evolved over time. Jared Kern is a...
« Older Entries
Next Entries »

Share this


Recent posts

  • GLP-1 RA prescription trends: January 2019 – March 2026
  • AMCP 2026: Impact of the CVS GLP-1 formulary change
  • AMCP 2026: Real-world adherence and MRI monitoring patterns among patients treated with lecanemab in the United States

Follow Truveta


Sign up for our newsletter

Ready to accelerate your research with representative, complete, and timely real-world data?

Truveta Data

Truveta Genome Project

Research

Resources

Blog

News

Careers

Privacy notice

Contact us

© Truveta 2026

Our website uses cookies to ensure you have the best experience.